Trials / Completed
CompletedNCT05730725
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986322 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2023-04-03
- Primary completion
- 2024-08-06
- Completion
- 2024-08-06
- First posted
- 2023-02-16
- Last updated
- 2025-11-25
- Results posted
- 2025-11-25
Locations
35 sites across 5 countries: United States, Australia, Canada, Japan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05730725. Inclusion in this directory is not an endorsement.